High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: Complete remission at transplantation is the major determinant of outcome - Lymphoma working party of the European group for blood and marrow transplantation

被引:108
|
作者
Kyriakou, Charalampia
Canals, Carmen
Goldstone, Anthony
Caballero, Dolores
Metzner, Bernd
Kobbe, Guido
Kolb, Hans-Jochem
Kienast, Joachim
Reimer, Peter
Finke, Jurgen
Oberg, Gunnar
Hunter, Ann
Theorin, Niklas
Sureda, Anna
Schmitz, Norbert
机构
[1] UCL, Northwood HA6 3NG, Middx, England
[2] European Bone Marrow Transplantat Grp, London, England
[3] Leicester Royal Infirm, Leicester, Leics, England
[4] Hosp Clin Serv Hematol, Salamanca, Spain
[5] Hosp Santa Creu & Sant Pau, E-08025 Barcelona, Spain
[6] Univ Hosp, Dept Med, Uppsala, Sweden
[7] Univ Freiburg, Dept Med Hematol Oncol, D-7800 Freiburg, Germany
[8] Univ Wurzburg, Med Klin, D-8700 Wurzburg, Germany
[9] Univ Munster, Dept Hematol Oncol, Munster, Germany
[10] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany
[11] Univ Dusseldorf, Dusseldorf, Germany
[12] Klin Oldenburg, Hamatol Onkol Abt, Oldenburg, Germany
关键词
D O I
10.1200/JCO.2007.12.6219
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Patients with angioimmunoblastic T-cell lymphoma (AITL) have poor prognoses with current conventional chemotherapy. The aim of this study was to evaluate the effect of high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) on patients with AITL. Patients and Methods We report a retrospective, multicenter study of 146 patients with AITL who received ASCT. The source of the stem cells was peripheral blood in 143 patients. The conditioning regimen varied, and 74% of the patients received carmustine and 1,3-bis(2-chloroethyl)-1-nitrosourea; etoposide; ara-C; and melphalan chemotherapy. Results After a median follow-up of 31 months (range, 3 to 174 months), 95 patients (65%) remained alive, and 51 patients (35%) died. Forty-two patients died as a result of disease progression, and nine died as a result of regimen-related toxicity. The cumulative incidence of nonrelapse mortality was 5% and 7% at 12 and 24 months, respectively. The actuarial overall survival (OS) was 67% at 24 months and 59% at 48 months. The cumulative incidence of relapse was estimated at 40% and 51% at 24 and 48 months, respectively. Disease status at transplantation was the major factor that impacted outcome. Patients who received a transplant during first complete remission (CR) had significantly superior progression-free survival and OS. The estimated PFS rates for patients who received their transplants in CR were 70% and 56% at 24 and 48 months, respectively; 42% and 30% for patients with chemotherapy-sensitive disease at those time points, respectively; and 23% at both time points for patients with chemotherapy- refractory disease. Conclusion This study shows that HDT and ASCT offers the possibility of long-term disease-free survival to patients with AITL. Early transplantation is necessary to achieve optimal results.
引用
收藏
页码:218 / 224
页数:7
相关论文
共 50 条
  • [1] High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (vol 26, pg 218, 2008)
    Kyriakou, C.
    Canals, C.
    Goldstone, A.
    Caballero, D.
    Metzner, B.
    Kobbe, G.
    Kolb, H. J.
    Kienast, J.
    Reimer, P.
    Finke, J.
    Oberg, G.
    Hunter, A.
    Theorin, N.
    Sureda, A.
    Schmitz, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3262 - 3262
  • [2] High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenstrom Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
    Kyriakou, Charalampia
    Canals, Carmen
    Sibon, David
    Cahn, Jean Yves
    Kazmi, Majid
    Arcese, William
    Kolbe, Karin
    Gorin, Norbert Claude
    Thomson, Kristy
    Milpied, Noel
    Niederwieser, Dietger
    Indrak, Karel
    Corradini, Paolo
    Sureda, Anna
    Schmitz, Norbert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2227 - 2232
  • [3] HIGH-DOSE THERAPY AND AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA
    KESSINGER, A
    ARMITAGE, JO
    SMITH, DM
    LANDMARK, JD
    BIERMAN, PJ
    WEISENBURGER, DD
    [J]. BLOOD, 1989, 74 (04) : 1260 - 1265
  • [4] Allogeneic Stem-Cell Transplantation in Patients With Waldenstrom Macroglobulinemia: Report From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
    Kyriakou, Charalampia
    Canals, Carmen
    Cornelissen, Jan J.
    Socie, Gerard
    Willemze, Roel
    Ifrah, Norbert
    Greinix, Hildegard T.
    Blaise, Didier
    Deconinck, Eric
    Ferrant, Augustin
    Schattenberg, Anton
    Harousseau, Jean-Luc
    Sureda, Anna
    Schmitz, Norbert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (33) : 4926 - 4934
  • [5] Allogeneic stem cell transplantation in angioimmunoblastic T-cell lymphoma (AITL): A retrospective survey from the lymphoma working party (LWP) of the European group for blood and marrow transplantation (EBMT)
    Kyriakou, Charalampia
    Canals, C.
    Taghipour, G.
    Finke, J.
    Kolb, H.
    Goldstone, A.
    Sureda, A.
    Schmitz, N.
    [J]. BLOOD, 2007, 110 (11) : 894A - 894A
  • [6] THE ROLE OF HIGH-DOSE THERAPY AND AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA
    STEWART, DA
    VOSE, JM
    WEISENBURGER, DD
    ANDERSON, JR
    RUBY, EI
    BAST, MA
    BIERMAN, PJ
    KESSINGER, A
    ARMITAGE, JO
    [J]. ANNALS OF ONCOLOGY, 1995, 6 (03) : 263 - 266
  • [7] Autologous Stem Cell Transplantation For Adult Burkitt Lymphoma In The Rituximab Era: A Retrospective Study Of The Lymphoma Working Party (LWP) Of The European Group For Blood and Marrow Transplantation (EBMT)
    Ahmed, Syed
    Boumendil, Ariane
    Finel, Herve
    Sureda, Anna
    Schouten, Harry C.
    Mohty, Mohamad
    van Imhoff, Guustaaf
    Schroyens, Wilfried
    Finke, Jurgen
    Schaap, Nicolaas P. M.
    Majolino, Ignazio
    Bargetzi, Mario
    Pogliani, Enrico Maria
    Afanasyev, Boris
    Dreger, Peter
    Aljurf, Mahmoud D.
    [J]. BLOOD, 2013, 122 (21)
  • [8] High-dose therapy and autologous blood stem cell transplantation in patients with follicular lymphoma
    Voso, MT
    Martin, S
    Abdallah, A
    Hohaus, S
    Ho, AD
    Haas, R
    [J]. BONE MARROW TRANSPLANTATION, 1999, 23 : S10 - S10
  • [10] AUTOLOGOUS STEM CELL TRANSPLANTATION FOR INTRAVASCULAR LARGE B-CELL LYMPHOMA: A RETROSPECTIVE STUDY OF THE OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION LYMPHOMA WORKING PARTY
    Meissner, J.
    Finel, H.
    Boumendil, A.
    Dietrich, S.
    Kanfer, E.
    Laboure, G.
    Abecasis, M.
    Cornelissen, J.
    Delage, J.
    Finke, J.
    Hess, U.
    Ludwig, H.
    Mohty, M.
    Pabst, T.
    Pioltelli, P.
    Robinson, S.
    Samaras, P.
    Dreger, P.
    [J]. HAEMATOLOGICA, 2016, 101 : 633 - 633